Phase IB/IIA Dose-Finding Safety and Activity Study of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) in HIV-Infected Subjects.

Trial Profile

Phase IB/IIA Dose-Finding Safety and Activity Study of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) in HIV-Infected Subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2012

At a glance

  • Drugs AMD 070 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Additional lead trial centrer identified as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 18 Jan 2009 Status changed from suspended to completed, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top